Skip to content

A clinical trial of extracorporeal shock wave(ESW) on upper limb flexor spasm post stroke

A clinical trial and mechanism exploration of extracorporeal shock wave(ESW) on upper limb flexor spasm post stroke based on neuroelectrophysiology evaluation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016144
Enrollment
Unknown
Registered
2018-05-14
Start date
2018-05-01
Completion date
Unknown
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper limb flexor spasm post stroke

Interventions

treatment group:ESW
control group:sham exposure

Sponsors

Zhujiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) to fulfill the consensus of "Diagnostic criteria for various cerebrovascular disease" during the fourth Congress of Cerebrovascular Disease in 1995, which also confirmed by head CT or MRI; (2) aged 25 to 80 with initial occurrence and stable condition; (3) upper limb flexor spasm of hemiplegia side; grade II or above in Modified Ashworth Scale(MAS); (4) no obvious cognitive impairment; (5) agreed to participate in ESW treatment and test.

Exclusion criteria

Exclusion criteria: (1) ever accepted treatment such as anti-spasm drugs , Botox injection and surgery etc.; (2) patient complicated by severe heart disease, arrhythmia and hypertension; (3) patient was presence of cardiac pacemaker; (4) patient with coagulation disorders; (5) patient with local infection and skin burst; (6) not agreed to participate in this study

Design outcomes

Primary

MeasureTime frame
MAS;

Secondary

MeasureTime frame
sEMG;MyotonPRO;IRT;

Countries

China

Contacts

Public ContactTao Fan

Zhujiang Hospital of Southern Medical University

fantaokf@163.com+86 18680288722

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026